Press Release Source: Advanced Healthcare Technologies, Inc.4
Advanced Hyperbaric Technologies, Inc. Announces the Commencement of a New Topical Hyperbaric Treatment Study Utilizing Its FDA Cleared, Rigid Extremity Chamber
Thursday January 23, 1:00 pm ET
FARMINGDALE, N.J., Jan. 23 /PRNewswire-FirstCall/ -- Advanced Hyperbaric Technologies, Inc., (AHT) a subsidiary of Advanced Healthcare Technologies, Inc. (OTC Bulletin Board: AVHC - News) announces the commencement of a new topical hyperbaric treatment study utilizing its FDA cleared, rigid extremity chamber and the disposable sacral unit which is patented and exclusively licensed to AHT.
Elaboration of Topical Hyperbaric Oxygen Study
In its continuing effort to document the benefits of topical hyperbaric oxygen treatment of wounds, Advanced Hyperbaric Technologies (AHT) has commenced the first in a series of planned studies of topical hyperbaric oxygen treatment on a variety of wound patients.
The latest study is being conducted at the Northeast Center for Special Care, a 275 bed traumatic brain and spinal cord injury rehabilitation center, by Dr. Bok Lee, a leading wound care specialist. The study will utilize a specialized oxygen measurement device called an Oximeter. The purpose is to demonstrate that topical hyperbaric treatment delivered by the FDA cleared rigid extremity chamber and the FDA cleared Sacral Unit manufactured by AHT actually increases the oxygen levels at the wound site, thereby eliminating the need, expense and possible risk of full body oxygen chamber treatment. One of the main goals of studies of this type is to generate clinical information necessary for Medicare and other insurance providers to pay for Topical Hyperbaric Oxygen Therapy in patient's homes as well as on an outpatient basis.
The initial patient being treated has a pressure ulcer which has been open for FOUR YEARS and has been treated with numerous forms of wound therapy, all of which have failed. In just 7 treatments (one week) with AHT's FDA cleared rigid extremity chamber the wound has decreased by 25%. Based upon this initial result, it is anticipated that the wound will be completely healed within 4 to 6 weeks!
"We are optimistic that the study will document the results that we have been witnessing with this first patient and will support our belief that topical hyperbaric treatment is the safest and most efficient means of delivering this limb and life saving treatment," stated President Phillip Loori.
With 17,000 nursing homes caring for patients, many of whom, (up to 23%) have ulcerated or chronic wounds coupled with the estimated 5,000,000 cases of open wounds which are reported each year and the estimated 10% of hospitalized patients who suffer from some form of chronic wound which requires specialized treatment, the implementation of AHT's product line to the wound care community is anticipated to provide much needed relief sooner, at less cost and in a safer manner than current treatment methods.
The commencement of a second research project which is now slated to begin in late February and will be conducted at a large Wound Care Center in New York. The research project will be a 100-patient controlled study. A controlled study of this size is significant as clinicians, when evaluating treatments, look for controlled studies with large numbers of patients treated.
AVHC has already signed a distribution agreement with Innovative Medical Systems, Inc. of St. Louis, Missouri, a medical distributor, who is marketing the chambers in the states of Illinois, Missouri and Kansas and with Randall Sulhoff of Omaha, Nebraska. As AVHC continues to increase its sales efforts in the United States they are beginning to focus on an even greater marketing opportunity, the international market.
AVHC is currently selling its products in Canada, Spain and Israel. AVHC is communicating with medical device distributors in Japan, Jordan and Ireland who have contacted the company seeking the opportunity to market the chambers in their respective countries. Additionally, AHT is working toward a strategic partner relationship with an overseas company to be the master distributor of its THBO products in Europe. The European market is of great interest to AVHC as diabetic foot ulcers continue to be the most common cause of lower extremity amputations in Europe.
About Advanced Healthcare Technologies ( OTCBB - AVHC )
Advanced Healthcare Technologies, Inc. is a company engaged in the acquisition and incubation of niche and proprietary technologies/companies in the healthcare industry.
About Advanced Hyperbaric Technologies
Advanced Hyperbaric Technologies, Inc. is a company engaged in the manufacture and sale of Topical Hyperbaric Oxygen Chambers and Sacral Units for the healing of open wounds. The chambers are marketed to hospitals, doctors, wound care clinics, nursing homes, and patients.
For further information, visit the Advanced Healthcare Technologies, Inc. website at www.advancedhealthcaretechnologies.com and visit the Advanced Hyperbaric Technologies website at www.advanced-hyperbaric.com , or contact Advanced Healthcare Technologies at 800-327-4325.
Please contact Pacifica Financial Group, 949-852-1812 for further information.
Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
--------------------------------------------------------------------------------
Source: Advanced Healthcare Technologies, Inc. |
